评估兴奋剂与非兴奋剂药物治疗成人注意缺陷多动障碍合并精神病或双相情感障碍病史的临床与成本效果随机对照试验:SNAPPER
SNAPPER是一项实用性、观察者盲法、多中心、双臂随机对照试验,计划招募244例18岁及以上有严重精神疾病(双相情感障碍或精神病)病史的注意缺陷多动障碍成人,随机接受兴奋剂(赖氨酸安非他明)或非兴奋剂(托莫西汀)治疗,主要结局为6个月时观察者评定的注意缺陷多动障碍症状严重程度。
要点
- 成人注意缺陷多动障碍合并严重精神疾病时,兴奋剂与非兴奋剂药物的疗效存在不确定性。
- NICE指南基于有限研究推荐兴奋剂一线使用,但该共病人群证据不足。
- SNAPPER试验旨在填补该证据空白,评估临床与成本效果。
核心结论
- SNAPPER试验旨在研究兴奋剂与非兴奋剂药物对有严重精神疾病病史的成人注意缺陷多动障碍患者的临床与成本效果。
研究设计与样本
- 实用性、观察者盲法、多中心、双臂随机对照试验,招募目标为244例18岁及以上有严重精神疾病(双相情感障碍或精神病)病史且确诊注意缺陷多动障碍的成人。
- 参与者经诊断筛查确认双相情感障碍或精神病及注意缺陷多动障碍诊断后,随机接受兴奋剂(赖氨酸安非他明)或非兴奋剂(托莫西汀)治疗。
主要发现
- 主要结局为6个月时观察者评定的注意缺陷多动障碍症状严重程度。
- 次要结局包括12个月时注意缺陷多动障碍症状严重程度、双相情感障碍或精神病症状的出现、健康相关生活质量、职业与日常功能、物质滥用、成本效果、依从性、合并用药及过程结局(6个月和12个月)。
关键数值与推荐
- NICE注意缺陷多动障碍指南指出现有证据不支持偏离其兴奋剂一线使用的主要推荐,但该推荐基于该共病人群的有限研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder involving inattention, hyperactivity and impulsivity, which starts in childhood and frequently persists into adulthood. Stimulant and non-stimulant medication are the mainstay of treatment in adults. ADHD in adults is commonly comorbid in people with severe mental illness (SMI) such as bipolar disorder (bipolar) and psychosis. There is substantial uncertainty over the effectiveness of stimulant and non-stimulant medication in adult ADHD comorbid with SMI. There is also concern that they could trigger or worsen psychotic or manic symptoms. Whilst National Institute of Health and Care Evidence (NICE) ADHD guidelines indicate available evidence does not justify a deviation from their main recommendations of using stimulants first line, this is based on limited studies within this comorbid population. A randomised controlled trial (RCT) is needed to address this evidence gap. We present a protocol for a pragmatic, observer-blind, multi-centre, two-arm, RCT called SNAPPER that aims to investigate the clinical and cost-effectiveness of stimulant compared with non-stimulant medication for adults with ADHD and a history of SMI. METHODS: The recruitment target is 244 participants, aged 18 years or above, who have a history of SMI (either bipolar disorder or psychosis) with ADHD. Having provided informed consent for screening, participants will undergo validated diagnostic screening assessments to re-confirm the diagnosis of bipolar or psychosis and confirm an ADHD diagnosis. Those with confirmed diagnoses will provide informed consent for entry to the main trial and will then be randomised to receive either stimulant (lisdexamfetamine) or non-stimulant (atomoxetine) medication. The primary outcome measure is observer-rated ADHD symptom severity at 6 months. Secondary outcomes include ADHD symptom severity at 12 months, emergence of symptoms of bipolar or psychosis, health-related quality of life, occupational, daily functioning, substance misuse, cost-effectiveness, adherence, concomitant medication and process outcomes at 6 and 12 months. DISCUSSION: Given that untreated ADHD is associated with poor clinical outcomes, unemployment and criminal justice system involvement, clear evidence in this area is likely to improve recovery for individuals with ADHD and a history of SMI, reducing costs for the individual, the NHS and society. TRIAL REGISTRATION: ISRCTN79796233. Registered on 19/05/2022. https://www.isrctn.com/ISRCTN79796233 .
引用
- Loi S, Joshee P, Ottridge R, et al. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPER. Trials. 2025. PMID: 41199289. doi:10.1186/s13063-025-09214-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。